360
Kidney Disease: Improving Global Outcomes
(KDIGO) guideline, 66, 221, 290
Kidney Early Evaluation Program (KEEP), 275
Kidney sympathetic innervation, 310
Korean Association REsource, 113
L
LDL-cholesterol, 6
Left ventricular hypertrophy (LVH), 240, 348
Left ventricular mass index (LVMI), 177, 267
Liquid chromatography–mass spectrometry
(LC–MS), 238
Liquorice, 46
Lisinopril, 33, 268
Loop diuretic, 222
LowSALT CKD study, 266
Lung ultrasonography (LUS), 177
M
Macroangiopathy, 29, 35
Malnutrition, 189
Mandibular advancement devices (MADs)
blood pressure, 211, 212
OSA, 210
Masked hypertension (MH), 42, 260
MASTERPLAN study, 80
Mechanoreceptors, 93
Melatonin hormone, 104
Membranoproliferative GN, 17
Mesangioproliferative GN, 17
Microalbuminuria, 64, 263
Microangiopathic nature, 16
Microangiopathy, 28, 29, 34
Microglia, 95–96
Microneurographic nerve traffic recordings, 153
Mild resistant hypertension, 313
Millennium Genome Project (MGP), 112
Mineralocorticoid Receptor Antagonists, 294, 298
Minoxidil, 34, 36, 228, 296
Modification of diet in renal disease (MDRD)
formula, 15, 145
Mononuclear phagocyte system (MPS), 170
Morisky Medication Adherence Scale, 69
Multiple Risk Factor Intervention Trial
(MRFIT), 287
Muscle sympathetic nerve activity (MSNA), 307
N
NaCl cotransporter (NCC), 98
National Kidney Foundation/Disease Outcomes
Quality Initiative (NKF/DOQI), 21
National Kidney Foundation Kidney Disease
Outcomes Quality Initiative
(KDOQI) guidelines, 296
Nephron numbers, 130
Neurogenic pathways
ET-1 system, 98
peripheral unit, 93
pre-sympathetic neurons, 93
sympathetic over-activation, 91–92
sympathetic pathway, 91
Nicotinamide adenine dinucleotide phosphate
(NADPH), 110
Nihilistic approach, 186
Nitric oxide, 133
NKF K/DOQI guidelines, 81
Nocturnal continuous positive airway
pressure, 206
Nocturnal dipping, 197
Nocturnal supplemental oxygen therapy, 212
Nonadherence, 346
Non-CKD populations
ambulatory systolic and diastolic BP, 60
antihypertensive medications, 66
aTRH, 65
cardiovascular events, 65
diuretics, 66
drug adherence, 60
drug compliance, 64
electronic health records, 66
isolated ambulatory hypertension (masked
hypertension), 64
left ventricular hypertrophy, 65
longitudinal healthcare insurance registry
data, 65
microalbuminuria, 64
multivariable-adjusted survival models, 60
plasma glucose levels, 64
pseudoresistance, 65
urinary albumin, 61
Noncommunicable diseases, 244
Nondiabetic nephropathy, 268
Non-dipping status, 42
Nonfatal CV events, 43, 50
Noninvasive arterial testing, 141
Non-nephrology setting, 46
Nonpharmacological interventional
methods, 310
Non-pharmacological suppression, 157–160
Nonresistant hypertension (non-RH), 66
Nonsteroidal anti-inflammatory drugs
(NSAIDs), 14, 84
Norepinephrine (NE), 151, 263, 308, 309
N-terminal prohormone brain natriuretic
peptide (NT proBNP), 175Index